We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+0.53%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$241M
AUM Growth
+$23.2M
(+11%)
Cap. Flow
+$29.8M
Cap. Flow
% of AUM
12.35%
Top 10 Holdings %
Top 10 Hldgs %
74.61%
Holding
31
New
8
Increased
10
Reduced
8
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$16.2M |
| 2 |
Ligand Pharmaceuticals
LGND
|
+$8.57M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$7.81M |
| 4 |
QuidelOrtho
QDEL
|
+$6.59M |
| 5 |
Xeris Biopharma Holdings
XERS
|
+$5.54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$12.3M |
| 2 |
Evolus
EOLS
|
+$10.9M |
| 3 |
ADMA Biologics
ADMA
|
+$4.34M |
| 4 |
Avalo Therapeutics
AVTX
|
+$2.57M |
| 5 |
OPTN
OptiNose
OPTN
|
+$2.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
ANI Pharmaceuticals
ANIP
$1.8B
| $733K | 0.3% |
26,060
-26,230
| -50% | -$978K |
|
|
MRNS
27
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $531K | 0.22% |
+56,747
| New | +$564K |
|
28
NeuroOne Medical Technologies
NMTC
$14.7M
| $273K | 0.11% |
41,351
-41,708
| -50% | -$505K |
|
29
Aldeyra Therapeutics
ALDX
$92.9M
| – | – |
-200,000
| Closed | -$800K |
|
|
30
Avalo Therapeutics
AVTX
$965M
| – | – |
-524
| Closed | -$2.57M |
|
|
CBAY
31
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-300,000
| Closed | -$1.01M |
|
Similar funds
ER
FDDB
VM
PF
SCM
CWM
EWM
RA
Stonepine Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Stonepine Capital Management held 31 positions worth $241M, up 11% from $218M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Stonepine Capital Management deployed $29.8M of net new capital in Q1 2022, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Amarin Corp: 245,636 shares worth $16.2M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier.
On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $12.3M trimmed.
- Stonepine Capital Management's largest Q1 2022 buy was Amarin Corp: 245,636 shares worth $16.2M.
- Stonepine Capital Management added most to Xeris Biopharma Holdings in Q1 2022, an estimated $5.54M increase.
- Stonepine Capital Management's biggest Q1 2022 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $12.3M.
- Stonepine Capital Management fully exited Avalo Therapeutics in Q1 2022, selling an estimated $2.57M.
- Stonepine Capital Management's ten largest holdings make up 75% of its $241M portfolio in Q1 2022.
- Stonepine Capital Management opened 8 new positions and closed 3 in Q1 2022.
- Stonepine Capital Management's portfolio value rose 11% quarter-over-quarter to $241M.
Based on Stonepine Capital Management's 13F filing for Q1 2022, filed 16 May 2022.